论文部分内容阅读
目的:探讨拉米夫定治疗代偿期乙型肝炎肝硬化患者过程中血清甲状腺激素的变化。方法:66例代偿期乙型肝炎肝硬化患者口服拉米夫定100 mg/d,疗程1年,分析患者治疗前后血清T3、T4、FT3、FT4和TSH检测结果。结果:治疗后患者血清T3、T4、FT3、FT4均较治疗前有显著改善(P<0.05),TSH水平治疗前后比较差异无统计学意义(P>0.05)。结论:代偿期乙型肝炎肝硬化患者服用拉米夫定,可使血清甲状腺激素水平获得明显改善。
Objective: To investigate the changes of serum thyroid hormone in patients with decompensated hepatitis B cirrhosis during lamivudine treatment. Methods: Sixty-six patients with decompensated hepatitis B cirrhosis were treated with lamivudine 100 mg once daily for one year. The serum T3, T4, FT3, FT4 and TSH levels before and after treatment were analyzed. Results: Serum T3, T4, FT3 and FT4 in patients after treatment were significantly improved compared with those before treatment (P <0.05). There was no significant difference in serum TSH levels before and after treatment (P> 0.05). Conclusion: Lamivudine in patients with compensated hepatitis B cirrhosis can significantly improve serum thyroid hormone levels.